Abstract
We present the efficient and stable encapsulation of doxorubicin within pH sensitive polymeric vesicles (polymersomes) for intracellular and nuclear delivery to melanoma cells. We demonstrate that PMPC25-PDPA70 polymersomes can encapsulate doxorubicin for long periods of time without significant drug release. We demonstrate that empty polymersomes are non-toxic and that they are quickly and more efficiently internalised by melanoma cells compared to healthy cells. Encapsulated doxorubicin has a strong cytotoxic effect on both healthy and cancerous cells, but when encapsulated it had a preferential effect on melanoma cells indicating that this formulation can be used to achieve an enhanced drug delivery to cancerous cells rather than to the healthy surrounding cells.
| Original language | English |
|---|---|
| Journal | Cancer Letters |
| Volume | 334 |
| Issue number | 2 |
| Pages (from-to) | 328-337 |
| Number of pages | 10 |
| ISSN | 0304-3835 |
| DOIs | |
| Publication status | Published - 2013 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Polymersomes
- Melanoma
- Targeted delivery
- Doxorubicin
Fingerprint
Dive into the research topics of 'Enhanced drug delivery to melanoma cells using PMPC-PDPA polymersomes'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver